Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 in moderate to severe platysma prominence
NCT07210463Phase 3Active, not recruiting
- Sponsor
- Merz
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of incobotulinumtoxinA in platysma prominence (3 arms), sponsored by Merz. Primary endpoint: Composite Achievement of Grade 1 or Grade 2 and at Least a 2-Grade Improvement From Baseline Based on Both the Investigator's Assessment and Participant's Self-Assessment Using the Merz Aesthetics… at 2 weeks. Started Oct 2025; status: active, not recruiting.
02
Drugs
incobotulinumtoxinA
03
Conditions
platysma prominence
Beyond the preview
Go deeper on NCT07210463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210463.